Posted by Michael Wonder on 04 Jun 2020
U.S. FDA accepts Pharmaessentia's application for ropeginterferon alfa-2b to treat polycythemia vera
4 June 2020 - U.S. team begins commercial preparations for novel pegylated interferon with appointment of General Manager Meredith Manning.
PharmaEssentia Corporation today announced that the U.S. FDA has recently accepted its biologics license application for ropeginterferon alfa-2b, a novel pegylated interferon intended for the treatment of the rare blood cancer polycythemia vera in the absence of symptomatic splenomegaly.
The company expects an agency decision in early 2021.
